# Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

> **NCT05362760** · PHASE4 · RECRUITING · sponsor: **Prof. Wolfgang Janni** · enrollment: 300 (estimated)

## Conditions studied

- Hormone Receptor-positive Metastatic Breast Cancer
- HER2-negative Metastatic Breast Cancer

## Interventions

- **DRUG:** Abemaciclib + Aromatase Inhibitor
- **DRUG:** Abemaciclib + Fulvestrant

## Key facts

- **NCT ID:** NCT05362760
- **Lead sponsor:** Prof. Wolfgang Janni
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-27
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05362760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05362760, "Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05362760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*